Jazz Pharmaceuticals
JAZZ
477 hedge funds and large institutions have $6.43B invested in Jazz Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 76 funds opening new positions, 163 increasing their positions, 160 reducing their positions, and 50 closing their positions.
82% more call options, than puts
Call options by funds: $28.9M | Put options by funds: $15.9M
52% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 50
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
5% more funds holding
Funds holding: 455 → 477 (+22)
2.37% more ownership
Funds ownership: 91.24% → 93.61% (+2.4%)
5% more capital invested
Capital invested by funds: $6.14B → $6.43B (+$292M)
2% more repeat investments, than reductions
Existing positions increased: 163 | Existing positions reduced: 160
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$75.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$72.9M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$53.9M |
| 4 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
+$32M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$30.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$136M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$65.8M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$65.7M |
| 4 |
BlackRock
New York
|
-$29.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$23.6M |
JAZZ Hedge Fund Activity: Q3 2024 in Review
477 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2024, worth a combined $6.43B — up 4.8% from $6.14B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new JAZZ positions and 50 closed out — a net gain of 26 holders — while 163 added to existing stakes and 160 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $75.9M. The largest seller was Baupost Group, exiting entirely with an estimated $136M sold.
- 477 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2024, up from 455 in Q2 2024.
- Funds reported $6.43B of Jazz Pharmaceuticals stock for Q3 2024, up 4.8% quarter-over-quarter.
- 76 funds opened new Jazz Pharmaceuticals positions in Q3 2024 and 50 closed out, a net change of +26 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2024 was EcoR1 Capital, an estimated $75.9M added.
- The largest Jazz Pharmaceuticals seller in Q3 2024 was Baupost Group, an estimated $136M sold.
Based on aggregated 13F filings for Q3 2024.